Fluid Biomarkers with Deep Phenotyping in Patients with ALS
This study is being performed to provide researchers with clinical information, combined with a wide range of biospecimens, to help identify biomarkers associated with amyotrophic lateral sclerosis (ALS), and to assess therapeutic targets. Participants will be asked to participate in four clinic visits and three telephone follow-up calls.
At each clinic visit, participants will have blood (including DNA and RNA) collected and will be evaluated with assessment tools focusing on motor neuron and cognitive (memory and thinking) functions.
Of the four visits in this study, three will also involve the collection of cerebrospinal fluid (CSF), and two will involve magnetic resonance imaging (MRI) cytography (a type of noninvasive body scan). Overall, participants may be in the research study for about 18 months.
Principal Investigator: Shafeeq Ladha, MD